Trial · NCT01970865
Results by group3,102
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 3,102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 10 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 25 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 50 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 75 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 100 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 150 mg QD (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 200 mg QD (Phase 1) | With DLT | 1 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 35 mg BID (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 75 mg BID (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 100 mg BID (Phase 1) | With DLT | 0 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 10 mg QD (Phase 1) | No DLT | 3 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 25 mg QD (Phase 1) | No DLT | 2 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 50 mg QD (Phase 1) | No DLT | 3 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 75 mg QD (Phase 1) | No DLT | 6 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 100 mg QD (Phase 1) | No DLT | 8 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 150 mg QD (Phase 1) | No DLT | 2 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 200 mg QD (Phase 1) | No DLT | 1 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 35 mg BID (Phase 1) | No DLT | 2 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 75 mg BID (Phase 1) | No DLT | 3 | Participants | |
| Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 | 100 mg BID (Phase 1) | No DLT | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01970865/results